Board of Governors of the Federal Reserve System, August 28, 1996.

William W. Wiles

Secretary of the Board

[FR Doc. 96–22469 Filed 9-3-96; 8:45 am]

BILLING CODE 6210-01-F

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices'' (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 17, 1996.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. Sun Bancorp, Inc., Selinsgrove, Pennsylvania; to engage *de novo* through its subsidiary, Anthony Court Associates, L.P., Bloomsburg, Pennsylvania, in community development activities, pursuant to § 225.25(b)(6) of the Board's Regulation Y.

B. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. I.S.B. Financial Corp., Oak Forest, Illinois; to engage *de novo* in making and servicing loans, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

C. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. Farmers Capital Bank Corporation, Frankfort, Kentucky; to engage *de novo* through its subsidiary, FCB Services, Frankfort, Kentucky, in providing data processing services to unaffiliated banks, including, but not limited to, general ledger, deposit systems, and loan systems, pursuant to § 225.25(b)(7) of the Board's Regulation Y. The geographic scope for these activities is Kentucky.

2. Mountain Bancshares, Inc., Yellville, Arkansas; to engage *de novo* through its subsidiary, The Bank of Yellville Financial Services, Yellville, Arkansas, in tax planning and preparation to be provided to individuals, businesses, corporations and nonprofit organizations, pursuant to § 225.25(b)(21) of the Board's Regulation Y. The geographic scope for these activities is Marion County, Arkansas and contiguous counties.

D. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. Citizens Development Company, Billings Montana; to engage *de novo* in data processing services, pursuant to § 225.25(b)(7) of the Board's Regulation Y. The geographic scope of this activity is Iroquois, South Dakota.

E. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. Plains Capital Corporation, Lubbock, Texas; to engage *de novo* through its subsidiary, Plains Service Corporation, Lubbock, Texas, in data processing, pursuant to § 225.25(b)(7) of the Board's Regulation Y. The geographic scope for this activity is Texas and New Mexico.

Board of Governors of the Federal Reserve System, August 28, 1996.

William W. Wiles

Secretary of the Board

[FR Doc. 96–22470 Filed 9-3-96; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96N–0266]

Agency Information Collection Activities: Proposed New Collection; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995, Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed survey of operating room nurse managers at health care facilities. The purpose of the survey is to estimate the proportion of the population at risk from the use of adhesive-backed tape to mark surgical instruments.

DATES: Submit written comments on the collection of information by November 4, 1996.

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Charity B. Smith, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1686.

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (the PRA), 44 U.S.C. 3501–3520, Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests

or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information listed below.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Surgical Instrument Marking Tape Survey

The mandate of FDA's Center for Devices and Radiological Health under the authority of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 301–395) and regulations contained in Title 21 of the Code of Federal Regulations includes the approval and adequate labeling of medical devices. Section 903(b)(2)(c) of the act (21 U.S.C. 393(b)(2)(c)) authorizes FDA to conduct research relating to medical devices.

The regulatory status of adhesive-backed, colored tape on medical devices is under review by FDA. The tape is frequently applied to medical devices, particularly surgical instruments, to facilitate sorting. It may be considered an accessory to medical devices used in surgical treatment as defined by 21 CFR 878.4800.

There are two case reports in the literature in which adverse events are attributed to the use of adhesive-backed, colored tape to mark surgical instruments (*Journal of Oral Maxillofacial Surgery*, 41:687–688, 1983; and *British Journal of Surgery*, 74:696, 1987). Two additional adverse event reports have been submitted to FDA.

The purpose of the survey is to estimate the proportion of the population at risk from this practice, and to determine if use of operating room nurse managers as proxies for sampling health care facilities for this purpose is effective. In addition, data will be collected to identify tape durability, extent of use, and whether there are any practices or procedures for marking surgical instruments and/or any human factors that could be altered to better protect the public health. Labeling information will also be collected.

The proposed randomized survey will be a one-time data collection effort. Completion of the survey is voluntary, and anonymity of individuals and institutions will be protected. Survey results will be available to participants upon request.

The only respondent burden will derive from the time needed to respond to survey questions. This will occur on a one-time basis. The length of the screening portion (questions 1 to 7) is estimated at 5 minutes, and the full survey length is estimated at an additional 25 minutes. Burden estimates are based on the need to have 308 surveys returned to achieve a statistically significant sampling.

FDA estimates the burden of this collection of information as follows:

ESTIMATED ANNUAL REPORTING BURDEN

Burden Element	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
Screening Questions Only (30%)	92	1	92	0.083	7.63
Complete Survey (70%)	216	1	216	0.50	108
TOTAL	308	-	-	-	115.63

There are no capital costs or operating and maintenance costs associated with this survey.

Dated: August 23, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–22441 Filed 9–3–96; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETING: The following advisory committee meeting is announced:

Antiviral Drugs Advisory Committee

Date, time, and place. September 26, 1996, 1 p.m. and September 27, 1996, 8:30 a.m., Holiday Inn—Gaithersburg, Goshen Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open committee discussion, September 26, 1996, 1 p.m. to 3 p.m.; open public hearing, 3 p.m. to 3:30 p.m., unless public participation does not last that long; open committee discussion, 3:30 p.m. to 5 p.m.; open committee discussion, September 27, 1996, 8:30 a.m. to 11 a.m.; open public hearing, 11 a.m. to 12 m., unless public participation does not last that long; open committee discussion, 12 m. to 4:30 p.m.; Rhonda W. Stover, Center for